About reviva pharmaceuticals holdings inc - RVPH
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.
RVPH At a Glance
Reviva Pharmaceuticals Holdings, Inc.
10080 North Wolfe Road
Cupertino, California 95014
| Phone | 1-408-501-8881 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -19,864,902.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
RVPH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.79 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.308 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.066 |
RVPH Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,418,921.571 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RVPH Liquidity
| Current Ratio | 2.076 |
| Quick Ratio | 2.076 |
| Cash Ratio | 1.985 |
RVPH Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -126.422 |
| Return on Equity | -419.967 |
| Return on Total Capital | -219.392 |
| Return on Invested Capital | -419.967 |
RVPH Capital Structure
| Total Debt to Total Equity | 4.705 |
| Total Debt to Total Capital | 4.494 |
| Total Debt to Total Assets | 2.555 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |